Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. Home

#ESMO21 Highlights on maintenance olaparib in ovarian cancer previously treated with PARPi

Eric Pujade-Lauraine reports on key results from ESMO Congress 2021 on LBA33 - Retreatment with maintenance olaparib in patients (pts) with ovarian cancer (OC) previously treated with a PARP inhibitor (PARPi): randomized Phase IIIb OReO/ENGOT Ov-38 trial

17 Sep 2021 Proffered Paper session - Gynaecological cancers

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.